CD274 and nasopharyngeal carcinoma: Activity of another anti-PD1 monoclonal antibody, pembrolizumab has been evaluated in multi-cohort, phase Ib clinical trial (KEYNOTE-028, NCT02054806) in patients with R/M NPC expressing PD-L1 (93.2%) (Table 3).